Clinical Trials

French biotech AdipoPharma has announced that it has secured funding for a clinical trial into its type 2 diabetes therapeutic, PATAS.

PATAS, a whole-body insulin sensitiser able to treat insulin resistance (the root cause of type 2 diabetes) works by restoring glucose uptake and utilisation in impaired adipocytes, or fat cells. This restarts healthy lipid biosynthesis, which leads to improved glycated haemoglobin (HbA1c) levels, and addresses the complications of the disease, which include diabetic neuropathy, cardiovascular dysfunction, liver disease and muscle loss.

AdipoPharma received funding from key global investors including Newton Biocapital, Sambrinvest, Investsud, Okeanos and Good Growth Capital. Trials will begin in mid-2025 in the US.

Dr Vincent Marion, president and CEO of AdipoPharma, commented, “PATAS represents a scientific breakthrough in our quest to treat insulin resistance, the primary cause of type 2 diabetes. We are so grateful to our global investors for their support as we prepare to begin clinical trials. Our vision is to create a world where insulin resistance and type 2 diabetes are no longer a life sentence.”